A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TACKLE
- Sponsors AstraZeneca
- 02 Nov 2023 Results (n=903) assessing analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 published in the Infectious Diseases and Therapy
- 26 Sep 2023 Results assessing effects of AZD7442 (tixagevimab/cilgavimab) on deaths from any cause or hospitalizations due to coronavirus disease 2019 (COVID-19) and symptom severity and longer-term safety in the TACKLE adult outpatients, published in the Infectious Diseases and Therapy
- 22 Dec 2022 This trial has been completed in Germany (End Date:19 Oct 2022) according to European Clinical Trials Database record.